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ABSTRACT 
Physical cues, such as extracellular matrix stiffness, direct cell differentiation and support tissue-specific 
function. Perturbation of these cues underlies diverse pathologies, including osteoarthritis, cardiovascular disease 
and cancer. However, the molecular mechanisms that establish tissue-specific material properties and link them 
to healthy tissue function are unknown. We show that Runx2, a key lineage-specific transcription factor, 
regulates the material properties of bone matrix through the same transforming growth factor-b (TGFβ)-
responsive pathway that controls osteoblast differentiation. Deregulated TGFβ or Runx2 function compromises 
the distinctly hard cochlear bone matrix and causes hearing loss, as seen in human cleidocranial dysplasia. In 
Runx2+/- mice, inhibition of TGFβ signalling rescues both the material properties of the defective matrix, and 
hearing. This study elucidates the unknown cause of hearing loss in cleidocranial dysplasia, and demonstrates 
that a molecular pathway controlling cell differentiation also defines material properties of extracellular matrix. 
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INTRODUCTION 
Tissues have characteristic material properties that arise largely from their extracellular matrices (ECMs), 
ranging from stiff bone and enamel (approximately 107 kPa) to compliant brain and skin (approximately 0.1–
250 kPa). In addition to their structural roles, the material properties of an ECM are powerful determinants of 
cell function. Similarly to biochemical signals, properties such as the elastic modulus direct cell differentiation 
and gene expression. Conversely, subtle changes in material properties of a tissue’s ECM disrupt cell 
proliferation and drive disease progression (Butcher et al, 2009). Mechanisms that regulate ECM material 
properties are, therefore, important in development and disease, but very little is known about these mechanisms, 
or the functional roles of ECM material properties in healthy tissues.  
The skeleton is an ideal model system in which to define mechanisms that establish ECM material properties and 
to understand their relationship with tissue-specific function. Healthy bone exhibits a variety of material 
properties depending on its skeletal location (Currey, 1999). Furthermore, factors that regulate ECM material 
properties were first discovered in the skeleton, including transforming growth factor-β (TGFβ). Alteration of 
TGFβ signalling in mice severely disrupts bone mass and the material properties of bone matrix (Balooch et al, 
2005)—including elastic modulus and hardness—which determine the ability of bone matrix to resist 
deformation. Although the effects of TGFβ on bone mass are due to its regulation of osteoblasts and osteoclasts 
(Mohammad et al, 2009), the cellular and molecular targets of TGFb in the control of bone matrix material 
properties are not known. 
TGFβ regulates osteoblast differentiation by targeting the lineage-specific transcription factor Runx2. In vitro, 
TGFβ represses Runx2 expression and function through a Smad3-dependent pathway that is essential for TGFβ 
to inhibit osteoblast differentiation (Alliston et al, 2001). The fact that TGFβ also represses Runx2 function in 
vivo is supported by the appearance of dysplastic clavicles and open cranial sutures in both Runx2+/- mice and in 
mice that overexpress TGFβ2 in osteoblasts (Erlebacher & Derynck, 1996; Otto et al, 1997). These are 
characteristics of the human genetic bone syndrome cleidocranial dysplasia (CCD), which results from RUNX2 
haploinsufficiency (Cooper et al, 2001). 
Patients with CCD also exhibit hearing loss (Visosky et al, 2003). Hearing loss in human CCD can be 
sensorineural (SNHL), conductive (CHL) or mixed. CHL occurs when sound cannot reach the cochlea in the 
inner ear due to problems in the external ear, tympanic membrane or middle ear. By contrast, SNHL results from 
cochlear, auditory nerve or central nervous system (CNS) defects. In many bone diseases, however, these clinical 
definitions blur, as in CCD, cochlear otosclerosis, Paget disease and osteogenesis imperfecta (Chole & 
McKenna, 2001; Hartikka et al, 2004; Monsell, 2004). For example, some cochlear otosclerosis patients exhibit 
SNHL without obvious damage to the organ of Corti or auditory nerve. Although these diseases highlight a role 
for bone in normal cochlear function, the mechanisms by which bone abnormalities cause SNHL are poorly 
understood. 
Owing to its specialized structure and function, cochlear bone presents a unique opportunity to study the 
regulation and role of bone matrix properties. Cochlear bone is protected from normal bone remodelling 
(Sorensen, 1994) and has been suggested to be the hardest bone in the body, although this assertion is based on 
clinical experience and intriguing studies of whale ear bone (Currey, 1999). Thus, we hypothesize that the matrix 
properties of cochlear bone are precisely calibrated and required for normal hearing. To test this hypothesis, we 
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evaluated bone matrix material properties and hearing in two mouse models of CCD, namely Runx2þ/ mice 
and D4 mice with increased TGFβ expression in osteoblasts. This study has broad implications for other tissues 
it allows exploration of the mechanisms by which tissue-specific ECM material properties are established and 
linked to healthy tissue function. 
RESULTS AND DISCUSSION 
Bone matrix material properties are anatomically distinct 
Although mouse models provide powerful tools with which to investigate the control of ECM material 
properties, most mouse bones are too small for macromechanical analyses. Nanoindentation measures material 
properties in the sub-micrometre range independently of bone size, porosity or shape (Rho et al, 1997). Using 
nanoindentation, we observed significant differences in the matrix elastic modulus of several mouse bones, 
ranging from the 30-GPa cochlear bone matrix to the 14-GPa calvarial bone matrix (Fig 1A). These data 
conclusively show that the cochlear capsule and ossicles are stiffer than other bones—as has been postulated 
previously (Currey, 1999)—and that ECM material properties depend on the anatomical identity of the bone. 
Increased TGFb disrupts the unique material properties of cochlear bone and hearing 
How are such differences in ECM material properties established and maintained? We previously identified 
TGFβ as a key regulator of bone matrix material properties (Balooch et al, 2005), but whether TGFβ also 
regulates bone quality in the unusual cochlear bone was unknown. Nanoindentation was used to evaluate 
cochlear bone from D4 mice that express an activated form of human TGFβ2 in osteoblasts under the control of 
osteocalcin promoter (Erlebacher & Derynck, 1996). The D4 cochlear bone matrix had decreased elastic 
modulus and hardness (Fig 1B,C), despite the lack of bone remodelling in the cochlea (Sorensen, 1994). 
 
Fig 1 Transforming growth factor-β overexpression disrupts cochlear bone matrix material properties and hearing. (A) The elastic modulus 
(GPa) of each bone is distinct. In the otic capsule, the (B) elastic modulus and (C) hardness of D4 cochlear bone matrix are reduced relative 
to WT (*P<0.01). (D) D4 mice (open squares) have elevated ABR thresholds for click and pure tone stimuli relative to WT (filled circles) 
(*P<0.001; #P<0.005). All error bars represent s.d. values. ABR, auditory brainstem response; TGFβ, transforming growth factor-β; WT, 
wild type. 
Presumably, tissue-specific material properties arise under selective pressure. Their functional importance has 
long been suggested (Currey, 1999), but is difficult to discern independently from other aspects of bone quality. 
To determine whether the decrease in cochlear bone hardness in D4 mice compromised cochlear function, we 
tested hearing in D4 and wild-type (WT) mice using the auditory brainstem response (ABR). An elevated 
auditory threshold, the lowest volume that elicits an ABR, indicates hearing loss. Stimuli included a multi-
frequency click and pure tones at 8, 16 and 32 kHz. The D4 mice had significantly elevated ABR thresholds 
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compared with WT (Fig 1D), with mean differences ranging from 13 to 16 dB. Therefore, increased TGFβ 
signalling in bone impaired both the material properties of cochlear bone and hearing, suggesting that the unique 
material properties of this tissue might be required for function. 
Runx2 insufficiency impairs hearing 
These observations raised two key questions. First, are defective bone matrix material properties responsible for 
hearing loss in D4 mice or in human disease? Second, what are the mechanisms by which TGFβ defines matrix 
material properties and hearing? A major clue came from the fact that both D4 and Runx2+/- mice have 
characteristics of CCD; a syndrome linked to loss of Runx2 function (Fig 2A). Another feature of human CCD is 
hearing loss (Cooper et al, 2001; Visosky et al, 2003), although hearing in Runx2+/- mice has not been evaluated. 
In this study, we observed that Runx2+/- mice have significantly higher ABR thresholds than WT mice (Fig 2B), 
similar to D4 mice. Compound action potentials (CAPs) were recorded to discriminate involvement of the CNS 
in hearing loss. The elevated CAP thresholds in Runx2+/- mice revealed that the CNS is not involved, thereby 
isolating hearing loss to the peripheral auditory system (Fig 2C). 
 
Fig 2 Runx2 insufficiency in mouse models of cleidocranial dysplasia impairs hearing. (A) X-ray confirmed absent clavicles (arrows) in 
Runx2+/- and D4 mice. (B) Runx2+/- mice (open triangles) exhibit higher ABR thresholds than WTs (filled circles) (*P<0.001). (C) CAP 
thresholds (click stimuli) were elevated in Runx2+/- mice. (D) Expression of Runx2 OC and nAchR-α9 mRNA in cochlear bone or soft 
tissue. ABR, auditory brainstem response; CAP, compound action potential; mRNA, messenger RNA; OC, osteocalcin; WT, wild type. 
Although Runx2 is typically restricted to mineralizing tissues, Runx2 has also been detected in neurons (Benes et 
al, 2007) and its expression in the cochlea is unknown. Unlike the hair-cellspecific nicotinic acetylcholine 
receptor α9, Runx2 messenger RNA was expressed only in microdissected cochlear bone or in the developing 
cochlear capsule (Fig 2D; supplementary Fig S1 online). Runx2 was not expressed by cells that give rise to the 
supporting or neural structures of the cochlea, demonstrating that the effects of Runx2 haploinsufficiency on 
hearing loss were due to a bone-intrinsic defect. 
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Sensorineural structures and bone anatomy of CCD-like ears are normal 
The CCD-like Runx2+/- and D4 mice are valuable tools to study the unexplained cause of SNHL in CCD and 
other bone diseases. Defects in the organ of Corti structure, hair cells, ganglion cells or other supporting cochlear 
structures cause SNHL. However, no differences in the sensorineural structures of the inner ear were observed in 
either Runx2+/- or D4 mice (Fig 3A,B; supplementary Fig S2 online). Together, three functional hearing tests 
(ABR, CAP and distortion product otoacoustic emission) localized the hearing defect to the peripheral auditory 
system and showed that conductive hearing remains largely intact, strongly suggesting a cochlear aetiology for 
hearing loss (Fig 2B,C; supplementary Fig S3 online). 
 
Fig 3 Mouse models of cleidocranial dysplasia lack discernible defects in cochlear structures. (A) No differences between WT, Runx2+/- and 
D4 cochleae were observed in the organ of Corti (orange arrow), spiral ligament, stria vascularis and spiral ganglia. (B) Phalloidin-stained 
organ of Corti showed normal organization with one IHC row and 3–4 OHC rows. Sterocilia (blue arrow) are normal in each strain. (C) 
Dissected ossicles (malleus (M), incus (I), stapes (S)) stained for bone and cartilage showed normal development and mineralization at 6 
days of age. (D) Micro-CT shows that each ossicle and the joints (green arrow) between them are intact. Apparent differences are artefacts of 
imaging at scanner resolution limits. CT, computed tomography; IHC, inner hair cell; OHC, outer hair cell; WT, wild type.  
As bone-intrinsic defects could cause hearing loss, we examined the outer, middle and inner ears of WT, 
Runx2+/- and D4 mice anatomically, radiologically and histologically. For example, OPG-/- mice exhibit gross ear 
bone defects, due to hyperactive osteoclasts, which cause hearing loss similar in magnitude to that in D4 and 
Runx2+/- mice (Kanzaki et al, 2006; Zehnder et al, 2006). However, our studies found no such defects (Fig 3C,D; 
supplementary Fig S2 online). Therefore, hearing loss in mouse models of CCD is not explained by overt 
developmental or anatomical defects in the skeletal or sensorineural structures of the ear. 
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Runx2 regulates bone matrix material properties and mineralization 
Next, we sought to determine whether hearing loss in Runx2+/- mice was due to the altered material properties of 
cochlear bone. Although TGFβ regulates bone material properties (Fig 1B,C), the underlying mechanisms for 
this are unknown. Furthermore, a role for Runx2 or any other transcription factor in the control of ECM material 
properties has not been reported. Nanoindentation revealed a reduction in the hardness and elastic modulus of 
Runx2+/- cochlear bone, relative to WT (Fig 4A,B). A major determinant of bone matrix material properties is 
the mineral content, which can be quantified using X-ray tomography (XTM). Using XTM, a shift was shown in 
the distribution of mineral content of Runx2+/- bone matrix relative to WT mice (Fig 4C). The decreased 
mineralization correlated with the decreased material properties of Runx2+/- bone matrix and resembled the 
reduced mineral content in D4 bone matrix (Balooch et al, 2005). We concluded that therefore, the osteoblast 
transcription factor Runx2 is a crucial regulator of the material properties and mineralization of bone matrix. 
Loss of cochlear bone matrix material properties accounts for HL 
Loss of the distinctive hardness of cochlear bone matrix in D4 and Runx2+/- mice was the only observed defect 
that could account for hearing loss in both strains, suggesting that the unique material properties of this tissue 
might directly affect its function. This was confirmed by a statistical analysis that related the auditory threshold 
to the elastic modulus of the cochlear bone matrix for the same ear. The elastic modulus correlated with ABR 
thresholds at 8 kHz, such that for every 1-GPa increase in elastic modulus, ABR thresholds dropped by 1.84 dB 
(sound pressure level; Fig 4D; P<0.01; R2=0.77). This relationship was independent of genotype. Therefore, the 
defective material properties of D4 and Runx2+/- bone matrix correlate significantly with hearing loss. 
 
Fig 4 Cochlear bone matrix material properties are regulated by Runx2 and are essential for hearing. The (A) elastic modulus and (B) 
hardness of cochlear bone matrix from Runx2+/- mice is reduced relative to WT (*P<0.01). (C) Reduced mineralization of Runx2+/- tibial 
bone as assessed by XTM. (D) Multiple linear regression analysis comparing elastic modulus with ABR thresholds for each ear shows that 
elastic modulus is a critical determinant of auditory function (P<0.01, R2=0.77). ABR, auditory brainstem response; WT, wild type; XTM, 
X-ray tomography. 
These results, to the best of our knowledge, provide the first direct evidence that ECM material properties are 
calibrated for their tissue-specific function. Furthermore, our results strongly suggest that changes in the 
specialized ear bone matrix material properties account for the unexplained SNHL in CCD. Although additional 
study is needed to elucidate the precise mechanisms for this, our findings might extend to hearing loss in 
Camurati–Engelmann disease, osteogenesis imperfecta and Paget disease, diseases which also result from 
defects in factors linked to bone quality (TGFβ, collagen and mineral, respectively; Higashi & Matsuki, 1996; 
Hartikka et al, 2004; Monsell, 2004; Balooch et al, 2005). 
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TGFβ represses Runx2 to regulate bone matrix material properties  
The similarity of the D4 and Runx2+/- bone phenotypes suggests that TGFb and Runx2 act via the same pathway. 
In vitro, TGFβ represses Runx2 (Alliston et al, 2001). Although Runx2 mutations that ablate its binding to bone 
morphogenetic protein- or TGFβ-activated Smads cause CCD (Zhang et al, 2000), the regulation of Runx2 by 
TGFβ in vivo remains unclear. As shown in Fig 5A, TGFβ repressed the expression of the Runx2-regulated 
genes, osteocalcin and Runx2, by 50% in D4 calvarial bone, relative to WT. Conversely, decreased TGFβ 
signalling in calvariae from DNTbRII mice—which express a dominant-negative TGFβ type II receptor in 
osteoblasts (Filvaroff et al, 1999)—increased Runx2 and osteocalcin messenger RNA levels (Fig 5B; 
supplementary Fig S4 online). These results indicate that, TGFβ represses Runx2 function in vivo and in vitro. 
Although transcription factors respond to growth factors in order to regulate gene expression and differentiation, 
their ability to control ECM material properties has not been explored. To determine whether Runx2 functions 
downstream from TGFβ in the control of bone matrix material properties, Runx2+/- mice were crossed with 
DNTβRII mice. We hypothesized that the Runx2+/- phenotype would be rescued by the inhibition of TGFb 
function. In DNTβRII; Runx2+/- mice, TGFβ inhibition did not rescue the clavicle dysplasia of Runx2+/- mice 
(Fig 5C). However, the reduced elastic modulus and hardness of Runx2+/- tibial bone matrix were rescued by 
inhibition of TGFβ signalling in osteoblasts (Fig 5D). Blocking the ability of autocrine TGFβ to repress Runx2 
function was also sufficient to rescue the defective mineralization of Runx2+/- bone. Unmineralized patches, 
apparent only in Runx2+/- bone, were absent in DNTβRII; Runx2+/- bone matrix (Fig 5E). Therefore, TGFβ 
regulates mineralization and matrix material properties through the same pathway that it uses to control cellular 
differentiation (Alliston et al, 2001), by repressing the activity of the lineage-specific transcription factor Runx2. 
Tissue-specific calibration of ECM material properties 
We investigated the mechanisms by which the distinctive material properties of a tissue are established and 
linked with its physiological function. Using bone matrix as a model, we identified Runx2 as a lineage-specific 
transcription factor that establishes ECM material properties through the same TGFβ pathway that controls 
osteoblast differentiation. This role of TGFβ and Smad3 extends beyond mineralized tissues, as Smad3 also 
controls skin ECM properties (Arany et al, 2006). Just as TGFβ regulates Runx2 function, it regulates other 
lineage-specific transcription factors to directly express tissue-specific ECM proteins, which in turn might 
influence ECM material properties. Therefore, this study elucidates the control of bone matrix quality and the 
role of bone in hearing. It also suggests a new paradigm in which signalling pathways and lineage-specific 
transcription factors cooperate to define the functionally essential ECM material properties of a specific tissue. 
METHODS 
Mice. The generation and skeletal abnormalities of D4, Runx2+/- and DNTβII mice have been described 
previously (Erlebacher & Derynck, 1996; Otto et al, 1997; Filvaroff et al, 1999). Mice were bred on a B6D2 × 
C57/Bl6 background. WT littermates were used as controls. Procedures were approved by the University of 
California San Francisco Institutional Animal Care and Use Committee. 
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Fig 5 Defective Runx2+/- bone matrix material properties, mineralization and hearing are rescued by inhibition of transforming growth 
factor-β. Quantitative reverse transcriptase–PCR shows the effect of (A) elevated TGFβ in D4 mice and (B) TGFb inhibition DNTbRII mice 
on gene expression in calvarial bone. X-rays, nanoindentation and TEM show that (C) clavicle dysplasia is not, but (D) elastic modulus 
(*P<0.001) and (E) mineralization are rescured in DNTβRII; Runx2+/- mice. (E) Arrows show sites lacking mineralization as detected through 
TEM. (F) ABR thresholds for Runx2+/- (open triangles), DNTβRII (asterisks) and DNTβRII; Runx2+/- (×), or WT mice (filled circles) are 
shown. ABR, auditory brainstem response; TEM, transmission electron microscopy; TGFβ, transforming growth factor-β; WT, wild-type. 
Auditory function. Evoked auditory brainstem response thresholds, compound action potentials and distortion 
product otoacoustic emissions were measured in 2-month-old male mice (nX4; Akil et al, 2006; Seal et al, 2008). 
Statistical analysis used one-way analysis of variance (P<0.05). 
Histology and analysis of gene expression. Cochlear histology studies were carried out on nX3 mice (Akil et 
al, 2006). Qualitative hair cell analysis was performed on dissected cochleae by microscopic visualization of 
rhodamine–phalloidin staining (nX3; Seal et al, 2008). Dissected ossicles from 1- and 6-day-old mice were 
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stained with Alizarin red and Alcian blue to visualize bone and cartilage, respectively (nX3; Otto et al, 1997). 
Gene expression was assessed using RNA isolated from dissected calvariae or cochlear bone or soft tissue (nX4; 
Seal et al, 2008; Mohammad et al, 2009). Using quantitative reverse transcriptase–PCR, amplification of Runx2, 
osteocalcin and nAchR-α9 were normalized to ribosomal protein L19. Statistical differences were calculated by 
Student’s t-test (P<0.05).  
Micro-computed tomography. Temporal bones, dissected with intact bulla to preserve the ossicular chain, were 
scanned by micro-computed tomography (n=3; VivaCT-40, Scanco). Image acquisition consisted of 418 slices 
encompassing the cochlea at 10.5-mm voxel size. For each 180°, 1,000 projections were taken. The integration 
time was 346, with potential of 55 kVp and current of 145 mA. The images were segmented using a low pass 
filter, and a threshold (0.7/1/270) was uniformly applied. For threedimensional reconstruction, cochlear bone 
was excluded to visualize the ossicular chain in 200–220 slices. 
Nanoindentation, XTM and transmission electron microscopy. For nanoindentation, cochleae were cut along 
the modiolar axis with a scalpel before mounting in epoxy resin. The malleus was mounted with epoxy without 
cutting or polishing. Using a saw, tibiae and femora were cut to expose mid-diaphyseal cortical bone, whereas 
calvariae were cut sagitally. Polished sections were nanoindented in load-control by using a Nanoscope III 
atomic force microscope (Veeco) with a Triboscope indenter head with a Berkovich tip (Hysitron; Mohammad et 
al, 2009). Indentations in three 30-mm lines with a 2-mm step size were placed across the cortical bone surfaces, 
but near the apex of the cochlea. Malleus material properties were determined using 10 indents per bone. 
Loading and unloading rates were 100 mN/s with a 10-s dwell time. For each bone, calculated elastic modulus or 
hardness values were averaged (25,26). Statistical analysis used one-way analysis of variance (P<0.05). XTM 
and transmission electron microscopy were performed as described previously (Mohammad et al, 2009; Thurner 
et al, 2010). 
Supplementary information is available at EMBO reports online (http://www.emboreports.org). 
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